AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Not Yet Opened 12-12 16:08:09

124.500

+7.100

+6.05%

High125.600	Low115.500	Vol9.91M
Open117.000	D1 Closing117.400	Amplitude8.60%
Mkt Cap114.66B	Tradable Cap114.66B	Total Shares921.00M
T/O1.21B	T/O Rate1.08%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":124.5,"timestamp":1765526889007,"preClose":117.4,"halted":0,"volume":9905117,"delay":0,"floatShares":921000000,"shares":921000000,"eps":-0.6670204840962167,"marketStatus":"Not Yet Opened","change":7.1,"latestTime":"12-12 16:08:09","open":117,"high":125.6,"low":115.5,"amount":1213765768,"amplitude":0.086031,"askPrice":124.5,"askSize":31000,"bidPrice":124,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.066466438151954,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":117.4,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":1.6011343041880726,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926/wiki","defaultTab":"wiki","newsList":[{"id":"1163186525","title":"AKESO Surges 6.8% After Major Announcement; Innovative Drug Leaders Rally, High-Beta HKSC Innovative Drug ETF (520880) Reverses Losses to Gain Over 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163186525","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163186525?lang=en_us&edition=fundamental","pubTime":"2025-12-12 14:41","pubTimestamp":1765521702,"startTime":"0","endTime":"0","summary":"On the afternoon of December 12, the Hong Kong Stock Connect (HKSC) innovative drug sector rebounded, with the high-beta HKSC Innovative Drug ETF (520880) turning positive and extending gains to over...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","520880","LU0348767384.USD","LU0561508036.HKD","LU1961090484.USD","LU0348825331.USD","LU1794554557.SGD","LU2778985437.USD","LU2399975544.HKD","LU0348784397.USD","09926","159992","LU2488822045.USD","BK1574","LU0348735423.USD","LU0348766576.USD","BK1161","IE00B5MMRT66.SGD","LU0634319403.HKD","LU0417516902.SGD","LU2476274308.USD","LU0417516571.SGD","IE00B543WZ88.USD","LU0540923850.HKD","LU0348827113.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU0348783233.USD","LU1720050803.USD","06978"],"gpt_icon":0},{"id":"1179623757","title":"HK Stock Movement | AKESO (09926) Rises Over 3% Again as FDA Approves Global Phase III Trial for Cadonilimab in First-Line Gastric Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1179623757","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179623757?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:17","pubTimestamp":1765509473,"startTime":"0","endTime":"0","summary":"AKESO (09926) surged over 3% again, reaching HK$121.9 by the time of writing, with a trading volume of HK$271 million. The company announced via its official WeChat account that the U.S. Food and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0348735423.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU1794554557.SGD","09926","LU0348767384.USD","LU0540923850.HKD","LU1720050803.USD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD","LU0348825331.USD","LU0348827113.USD","LU0348784397.USD","LU2399975544.HKD","LU2476274308.USD","LU0417516571.SGD","LU2778985437.USD","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","LU0417516738.SGD"],"gpt_icon":0},{"id":"2590526204","title":"FDA Clears Akeso Inc. to Begin Global Phase III Trial of Cadonilimab in First-Line Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526204","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526204?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:32","pubTimestamp":1765506750,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5q2jL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0348735423.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU1794554557.SGD","09926","LU0348767384.USD","LU0540923850.HKD","LU1720050803.USD","BK1574","LU2488822045.USD","IE00B5MMRT66.SGD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD","LU0348825331.USD","LU0348827113.USD","LU0348784397.USD","LU2399975544.HKD","LU2476274308.USD","LU0417516571.SGD","LU2778985437.USD","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","LU0417516738.SGD"],"gpt_icon":0},{"id":"2590952620","title":"Cadonilimab (Pd-1/Ctla-4) Receives FDA Clearance for Global Phase Iii First-Line Gastric Cancer Trial Versus Nivolumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2590952620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590952620?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:32","pubTimestamp":1765506735,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA3XSZWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0540923850.HKD","LU0417516738.SGD","LU2778985437.USD","09926","LU0348767384.USD","LU0348784397.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU1961090484.USD","LU2476274308.USD","LU2399975544.HKD","BK1574","LU0561508036.HKD","LU0348783233.USD","LU0634319403.HKD","LU0348825331.USD","LU0417516571.SGD","LU0348735423.USD","LU0348766576.USD","LU2488822045.USD","BK1161","LU1720050803.USD","LU1794554557.SGD","LU2476274720.SGD","LU0417516902.SGD"],"gpt_icon":0},{"id":"1149122114","title":"HK Stock Movement | AKESO (09926) Rises Over 3% in Early Trading as Updated Data on Ivonescimab for First-Line TNBC Treatment Released at ESMO IO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1149122114","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149122114?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:00","pubTimestamp":1765418424,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw an early trading surge of over 3%, reaching a 2.83% increase to HK$120.2 by the time of reporting, with a trading volume of HK$100 million. On December 11, AKESO announced via its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU1794554557.SGD","LU0348827113.USD","LU0417516571.SGD","LU0561508036.HKD","LU2488822045.USD","LU0417516902.SGD","LU0417516738.SGD","LU0348766576.USD","LU2778985437.USD","BK1574","LU0634319403.HKD","LU0348825331.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU2476274720.SGD","LU1961090484.USD","BK1161","LU2399975544.HKD","LU0348784397.USD","LU0348735423.USD","LU1720050803.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD","LU0348783233.USD","LU2476274308.USD"],"gpt_icon":0},{"id":"2590550941","title":"Akeso Reports 80% Response Rate for Ivonescimab Plus Chemotherapy in First-Line TNBC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590550941","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590550941?lang=en_us&edition=fundamental","pubTime":"2025-12-11 09:54","pubTimestamp":1765418043,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced updated efficacy data from a Phase II clinical study evaluating ivonescimab, a PD-1/VEGF bispecific antibody, in combination with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer . The results were presented at the 2025 European Society for Medical Oncology Immuno-Oncology Congress  in London. As of July 15, 2025, 36 patients were enrolled, with the objective response rate  reported at 80.0% and a disease control rate  of 100.0%. The median progression-free survival  was 15.2 months. The safety profile was favorable, with no treatment-related adverse events leading to discontinuation or death. Overall survival data are not yet mature. A Phase III clinical trial for this indication is currently ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL944TSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0348766576.USD","LU2399975544.HKD","LU0634319403.HKD","LU2488822045.USD","LU2476274308.USD","LU0348767384.USD","LU0348783233.USD","09926","LU2778985437.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU0417516902.SGD","LU2476274720.SGD","LU0348827113.USD","LU0348784397.USD","BK1574","LU1961090484.USD","IE00B543WZ88.USD","LU0417516738.SGD","LU0540923850.HKD","LU1794554557.SGD","LU1720050803.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","BK1161"],"gpt_icon":0},{"id":"1195995366","title":"BOCOM INTL: Medical Insurance and Commercial Insurance Catalogs Implemented, Diversified Payment Systems to Drive Incremental Space for Innovative Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1195995366","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195995366?lang=en_us&edition=fundamental","pubTime":"2025-12-10 14:40","pubTimestamp":1765348821,"startTime":"0","endTime":"0","summary":"According to a research report by BOCOM INTL, the firm maintains a leading rating for China's pharmaceutical industry. The National Healthcare Security Administration recently held the \"2025...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","159992","BK1147","LU0348735423.USD","IE00BPRC5H50.USD","06978","LU0455707207.USD","BK1583","01177","LU1961090484.USD","LU1794554557.SGD","09926","BK1515","LU0348767384.USD","LU0540923850.HKD","LU1720050803.USD","LU1969619763.USD","IE00BZ08YS42.EUR","BK1574","LU0359202008.SGD","LU2097828474.EUR","IE00B5MMRT66.SGD","BK1161","LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU2242644610.SGD","IE00BZ08YR35.GBP","LU0348783233.USD","BK1589","01801","LU0348825331.USD","LU1023057109.AUD","LU0348827113.USD","BK1521","LU0348784397.USD","BK1191","LU0359201612.USD","LU0502904849.HKD","LU2328871848.SGD","LU2097828631.EUR","LU2399975544.HKD","LU2476274308.USD","LU2543165471.USD","LU0417516571.SGD","LU0359201885.HKD","03329","LU2097828714.EUR","LU2778985437.USD","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","LU0417516738.SGD","01276"],"gpt_icon":0},{"id":"2590330385","title":"Assessing Akeso (SEHK:9926) After Its Strong Year-to-Date Rally and Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2590330385","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590330385?lang=en_us&edition=fundamental","pubTime":"2025-12-10 09:46","pubTimestamp":1765331202,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has quietly turned into one of those stocks long term investors keep revisiting, with strong year to date gains despite recent pullbacks. This makes its current valuation worth a closer look.\nSee our latest analysis for Akeso.\nThat backdrop helps explain why a recent cool off in the share price, including a 4.0% one day share price pullback to HK$119.4, sits alongside a powerful year to date share price return of roughly 104%. Longer term total shareholder returns are still...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-after-its-strong-year-to-date-rally","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-after-its-strong-year-to-date-rally","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2488822045.USD","LU0417516738.SGD","LU1720050803.USD","LU0348825331.USD","LU2476274308.USD","IE00BPRC5H50.USD","BK1161","LU0417516902.SGD","LU1794554557.SGD","LU2399975544.HKD","09926","LU2778985437.USD","IE00B5MMRT66.SGD","LU0348827113.USD","LU0417516571.SGD","LU0348767384.USD","LU0634319403.HKD","LU0348783233.USD","LU0348784397.USD","LU0348735423.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348766576.USD","LU2476274720.SGD","LU0561508036.HKD","BK1574","LU1961090484.USD"],"gpt_icon":0},{"id":"2590207313","title":"Akeso Reports 100% R0 Resection Rate in Phase II Cadonilimab Study for Resectable Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590207313","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590207313?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:51","pubTimestamp":1765266685,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced results from a Phase II clinical study  evaluating its PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with the SOX regimen as neoadjuvant therapy for resectable gastric or gastroesophageal junction adenocarcinoma. The data, presented at the 2025 ESMO Asia Congress, showed a 100% R0 resection rate among patients who underwent surgery, with 85.7% achieving primary tumor downstaging and 75.0% achieving nodal downstaging. The overall pathologic complete response  rate was 28.6%, and the major pathologic response  rate was 71.4%. Safety findings were consistent with previously known profiles, and no new safety signals were observed. Akeso Inc. is also conducting a pivotal Phase III trial  of cadonilimab combined with SOX for perioperative treatment in this patient population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8xVxf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0348766576.USD","LU0540923850.HKD","09926","LU2476274308.USD","LU0417516738.SGD","LU0348827113.USD","LU0634319403.HKD","LU2488822045.USD","IE00B543WZ88.USD","LU0417516902.SGD","LU0348735423.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU0561508036.HKD","LU0348825331.USD","LU0348784397.USD","BK1574","LU1794554557.SGD","LU0348783233.USD","LU2778985437.USD","LU2399975544.HKD","LU2476274720.SGD","LU0417516571.SGD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0348767384.USD"],"gpt_icon":0},{"id":"1148369497","title":"Hong Kong Stock Connect Innovative Drug Sector Accelerates Decline in Afternoon, AKESO Drops Over 5%! Pure Innovative Drug ETF \"520880\" Falls Over 2% as Premium Surges","url":"https://stock-news.laohu8.com/highlight/detail?id=1148369497","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148369497?lang=en_us&edition=fundamental","pubTime":"2025-12-09 14:40","pubTimestamp":1765262452,"startTime":"0","endTime":"0","summary":"On the afternoon of December 9, the Hong Kong Stock Connect innovative drug sector accelerated its decline, with the pure innovative drug ETF—HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU0417516902.SGD","LU0348767384.USD","LU0417516571.SGD","LU0348766576.USD","LU2778985437.USD","LU0561508036.HKD","520880","BK1574","LU2476274720.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU1720050803.USD","LU0417516738.SGD","LU2476274308.USD","159992","IE00B543WZ88.USD","LU0540923850.HKD","LU0348827113.USD","LU0348784397.USD","BK1161","LU2488822045.USD","LU0348735423.USD","LU1961090484.USD","06978","IE00B5MMRT66.SGD","LU1794554557.SGD","LU0348825331.USD","09926","LU0634319403.HKD"],"gpt_icon":0},{"id":"2590393378","title":"Akeso Reports Ivonescimab Plus Chemotherapy Improves Survival and Quality of Life in Advanced Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393378","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590393378?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:03","pubTimestamp":1765245813,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced updated results from the pivotal Phase III HARMONi-6 study evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer . The data, presented at the 2025 ESMO Asia Congress, showed that the ivonescimab regimen significantly prolonged progression-free survival and improved patient-reported quality of life compared to a tislelizumab-based regimen. The supplemental New Drug Application for this indication was accepted for review by China's National Medical Products Administration in July 2025. Results from the HARMONi-6 study further support the clinical value of ivonescimab in this setting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL7RCdvp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU0540923850.HKD","09926","LU2778985437.USD","LU2399975544.HKD","LU1961090484.USD","LU0417516902.SGD","LU2476274720.SGD","LU0417516571.SGD","LU2476274308.USD","LU0561508036.HKD","LU2488822045.USD","IE00BPRC5H50.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348827113.USD","LU0348767384.USD","LU1794554557.SGD","LU0348784397.USD","LU0348766576.USD","BK1574","BK1161","LU1720050803.USD","LU0348783233.USD","LU0417516738.SGD","LU0348825331.USD","LU0348735423.USD"],"gpt_icon":0},{"id":"2589278875","title":"Akeso's Five Innovative Drugs Gain Full Inclusion in China's 2025 National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589278875","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589278875?lang=en_us&edition=fundamental","pubTime":"2025-12-07 14:18","pubTimestamp":1765088324,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on December 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL4V3wLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","LU1794554557.SGD","LU2778985437.USD","LU0348767384.USD","LU0634319403.HKD","BK1574","LU0348735423.USD","LU0348827113.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0540923850.HKD","LU1961090484.USD","LU0348766576.USD","09926","IE00B543WZ88.USD","BK1161","LU0417516902.SGD","LU0348825331.USD","LU0417516738.SGD","LU0561508036.HKD","LU2399975544.HKD","LU2476274720.SGD","LU2488822045.USD","LU2476274308.USD","LU0348783233.USD","LU1720050803.USD","NHC","IE00B5MMRT66.SGD","BK4185"],"gpt_icon":0},{"id":"1146416783","title":"Akeso, Inc. (09926) Announces Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1146416783","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146416783?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:49","pubTimestamp":1764838157,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (Stock Code: 09926) submitted its monthly return for the period ended 30 November 2025. According to the announcement, the company’s authorized share capital remains at 5,000,000,000...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU1102505762.USD","BK1100","BK1221","LU0228659784.USD","BK1160","SG9999015945.SGD","BK1209","LU0572944931.SGD","LU1969619763.USD","BK1158","BK1606","LU0048575426.USD","LU0164872284.USD","LU1497733557.USD","LU0039217434.USD","LU0594300419.USD","LU2543165471.USD","06168","03998","02020","01939","BK1556","06657","IE00BQXX3D17.EUR","03658","IE00BQXX3C00.GBP","IE00BGV7N243.SGD","LU0540923850.HKD","SGXZ62798434.SGD","01530","BK1589","LU2357125470.USD","SGXZ86797644.SGD","BK1207","09877","LU0737861699.HKD","02451","BK1155","BK1554","SG9999014674.SGD","01093","02469","LU0345776255.USD","LU0823426480.USD","03800","HK0000252152.HKD","LU1720050803.USD","LU0708995583.HKD","LU1861219969.SGD","LU1366334651.USD","06633","LU0348825331.USD","LU2476274308.USD","01119","BK1527","HK0000306701.USD","LU0164865239.USD","BK1117","LU0509642566.USD","LU1224709979.USD","09660","BK1125","BK1214","LU1039395188.USD","09699","BK1516","80020","LU0823038988.USD","06090","BK1524","BK1617","IE00B8L5B284.USD","LU0175139822.USD","SG9999004311.SGD","LU1267930227.SGD","BK1608","02177","BK1591","LU0067412154.USD","LU1226288253.USD","LU1880383440.USD","LU0541502299.USD","LU1939255532.USD","LU0823397103.USD","01739","SG9999015986.USD","HK0000320223.HKD","LU1048588211.SGD","BK1604","LU0456827905.SGD","SG9999001226.SGD","LU1880383366.USD","02565","LU1235295612.USD","03709","BK1258","01384","SG9999015952.SGD","LU0310800965.SGD","LU0348827113.USD","LU1522347837.USD","LU1152091754.HKD","LU0348767384.USD","82331","00384","BK1190","03145","BK1195","LU0463099449.HKD","09690","00460","01519","BK1557","01880","002594","LU0880133367.SGD","LU1211504680.USD","06609","02392","LU0128525689.USD","LU1960683339.HKD","BK1227","00451","BK1164","00992","02331","06862","LU0561508036.HKD","BK1239","BK1240","IE0034224299.USD","02298","BK1571","LU0082770016.USD","LU0289739343.SGD","LU1497733631.SGD","BK1193","06996","03396","LU1981816686.USD","BK1542","HK0000252160.HKD","IE00BVYPNP33.GBP","LU0348805143.USD","SG9999001051.SGD","IE00B0JY6N72.USD","LU0370786039.SGD","06069","06186","01783","IE00BYV24P56.USD","LU0048580855.USD","LU0469268626.HKD","LU0314109678.HKD","00826","BK1520","ANPDY","02886","BK1564","BK1119","LU0164939612.USD","00305","LU0516422440.USD","LU0593848301.USD","01818","02145","BK1222","BK1574","BK1509","LU1226287875.USD","LU0605514214.HKD","09990","LU1008478684.HKD","02629","LU1102505929.USD","IE00BPRC5H50.USD","LU2097828631.EUR","LU2778985437.USD","02121","LU1861214812.USD","LU0819123356.HKD","BK1212","09955","IE0009570106.USD","01177","BK1178","00017","BK1237","06138","LU0634319403.HKD","LU0828237510.HKD","LU1188198961.HKD","BK1225","SG9999001903.USD","01440","02509","03680","02155","BK1541","BK1147","LU0501845795.SGD","BK1230","BK1521","09890","02171","SG9999015978.USD","01640","01211","02420","LU0511384066.AUD","LU0543330566.HKD","BK1179","09923","BK1502","LU0269904917.USD","IE00BZ08YT58.USD","BK1143","BK1515","LU2449936058.SGD","01907","02650","LU1366334578.USD","LU0417516902.SGD","BK1257","IE0003851619.USD","LU1675838814.USD","01735","BK1124","01952","02142","LU1956131251.USD","IE00BZ08YS42.EUR","LU2153592121.USD","LU0871576103.HKD","LU1023057109.AUD","06100","02419","LU0823414478.USD","LU0348783233.USD","BK1141","LU2097828805.USD","LU1634259391.SGD","00267","LU1226287529.USD","LU0214875030.USD","LU0516422952.EUR","LU0650527681.SGD","06618","LU0052756011.USD","LU0320764599.SGD","IE0003795394.USD","BK1253","IE00BZ08YR35.GBP","BK1613","LU0417516738.SGD","LU2663582299.SGD","01164","02268","LU2177674079.SGD","BK1168","LU1794554557.SGD","LU0011963245.USD","LNNGY","LU0261950470.USD","LU0588545490.SGD","01520","LU0856984785.SGD","LU0762540952.USD","09878","02380","BK1616","00382","LU0516422366.SGD","LU0072462343.USD","01809","LU0868486357.SGD","BK1544","LU3063872942.SGD","LU0516423091.SGD","LU2328871848.SGD","BK1593","HYDD.SI","LU1303224171.USD","LU0165289439.USD","01405","LU0164880469.USD","BK1560","06855","LU0499858602.USD","03677","09911","06608","02150","LU0828238088.HKD","BK1128","09678","LU0516423174.USD","SG9999002828.SGD","LU0737861772.HKD","LU0259732245.USD","BK1114","BK1200","BK1161","09926","02158","BK1597","BK1522","LU0702159699.USD","BK1566","02276","BK1134","02567","IE00B031HY20.USD","BK1183","BK1610","LU0052750758.USD","02696","01448","LU0326950275.SGD","01458","LU1868837565.USD","00135","09639","06677","00875","SG9999002950.SGD","LU1328615791.USD","HK0000306685.HKD","LU1166156734.SGD","LU1497734951.SGD","LU2045819591.USD","01117","BK1229","03836","LU1961090484.USD","09927","LU1481107354.HKD","02057","BK1618","LU2023250504.SGD","LU1226287792.SGD","LU1770036033.HKD","LU0572939691.SGD","03738","BK1539","SG9999011746.SGD","02595","LU0054450605.USD","IE00B5MMRT66.SGD","06683","00855","LU2242644610.SGD","BK1096","BK1609","LU1868838027.USD","LU2238339852.HKD","LU2294711713.HKD","02273","SG9999001069.SGD","LU2106854487.HKD","SG9999000459.SGD","IE00B543WZ88.USD","LU1770034418.SGD","00999","BK1111","09996","LU2097828557.USD","IE00BVYPNQ40.USD","LU2476274720.SGD","06919","BK1512","LU0823414551.USD","LU1282649067.USD","BK1531","BK1619","LU0287142896.SGD","LU0823426308.USD","00363","LU0315179316.USD","LU0431992006.USD","BK1559","BK1553","LU1868837722.USD","BK1144","LU0455707207.USD","02250","LU0327786744.USD","02460","IE0008369823.USD","LU0329678170.USD","LU0449515922.USD","LU0149721374.USD","LU0572940350.SGD","02096","BK1126","BK1220","LU0244354667.USD","BK1592","03896","LU0348735423.USD","LU1807302812.USD","LU0251143458.SGD","LU2249611893.SGD","LU1282649810.SGD","LU2039709279.SGD","LU1328277881.USD","01276","02157","00003","BK1110","02256","BK1578","LU0588545904.SGD","02411","LU0488056044.USD","BK1139","LU1242518931.SGD","LU0502904849.HKD","BK1528","LU0359201885.HKD","01833","BK1575","00960","02858","LU0289960550.SGD","LU0611395673.USD","LU0251144936.SGD","01333","BK1233","BK1163","BK1228","LU1974910355.USD","BK1518","BK1109","02167","06988","02552","03650","LU0048597586.USD","LU1993786604.SGD","09636","HK0000500386.USD","02556","BK1104","BK1594","03681","BK1526","LU2348773727.SGD","01651","BK1549","BK1540","BK1548","LU0449509016.USD","LU2008162690.USD","BK1167","LU0315178854.USD","82020","LU0620787316.HKD","02018","01969","02616","LU0819121731.USD","LU0289961442.SGD","00699","LU2360107325.USD","02598","BK1127","BK1188","BK1583","LU0211977185.USD","SG9999004220.SGD","LU2506952253.HKD","LU2153591404.USD","02315","02100","BK1550","LU0588546209.SGD","LU0791591158.USD","00656","IE00BQXX3F31.USD","LU0072913022.USD","LU2399975544.HKD","02279","IE00B0169L03.USD","LU0417516571.SGD","SG9999006597.SGD","BK1169","01585","LU0107464264.USD","BK1215","BK1504","BK1216","LU0348784397.USD","LU0307460666.USD","LU0348766576.USD","IE00B031J352.USD","LU0229945570.USD","LU0505663152.USD","LU0531971595.HKD","09919","02525","LU0140636845.USD","LU0143863784.USD","LU1634259557.SGD","BK1142","LU0359201612.USD","BK1194","LU0541501648.USD","00302","BK1595","LU1251922891.USD","BK1586","LU0254981946.USD","BK1555","02228","LU0791590937.USD","BK1590","00777","06821","02511","01762","81211","SG9999003461.SGD","00798","06060","LU0054237671.USD","LU0173614495.USD","02551","09860","LU0084288322.USD","01070","09961","01911","BK1607","BK1151","BK1095","IE00B29SXG58.USD","LU2506951792.HKD","00136","02197","LU1242518857.USD","BK1171","02533","LU0231483743.USD","BK1582","06086","LU0823437842.USD","BK1530","LU0823397285.USD","LU0384037296.USD","BK1219","BK1579","LU1831875114.USD","BK1224","BK1598","LU0499858438.USD","09880","01378","BK1615","09959","BK1148","02488","IE00BD6J9T35.USD","LU0831093199.SGD","LU0261947096.USD","IE00B8HQ1Z84.USD","LU2298064838.USD","02105","BK1175","LU0264606111.USD","IE0008368742.USD","86618","BYDDY","LU2460026573.USD","01471","SG9999000475.SGD","BK1500","SG9999002562.SGD","BK1519","LU1115378108.SGD","LU0823039010.USD","80992","01773","LU1951186391.HKD","BK1136","SG9999000418.SGD","SG9999006514.SGD","BK1140","BK1588","LNVGY","BK1154","BK1585","01877","00666","02587","BK1600","LU1046422090.SGD","LU2348774022.SGD","BK1605","BK1197","LU0865486749.SGD","LU1152091168.USD","00861","LU2125910500.SGD","LU0456846285.SGD","02670","IE00BGHQDM52.EUR","BK1186","SG9999002463.SGD","02382","LU1917777945.USD","LU2097828714.EUR","HK0000165453.HKD","00512","BK1131","LU0345775950.USD","BK1247","BK1137","BK1150","SGXZ90724238.SGD","LU2097828474.EUR","02400","BK1198","02013","BK1189","LU1808992512.USD","LU1719994722.HKD","01600","02431","LU0043850808.USD","LU0640798160.USD","02190","02436","01681","LU0531970944.HKD","02506","BK1596","LU0979878070.USD","LU0588545730.USD","IE0032431581.USD","BK1235","06160","BK1552","LU0594300179.USD","09956","BK1587","SG9999001093.SGD","LU1813983027.USD","01318","IE0031814852.USD","LU0261950983.USD","LU1508157978.USD","IE00BMCWC346.EUR","LU0274383008.USD","02498","LU0359202008.SGD","06963","00884","LU0082770016.SGD","BK1191","00300","06913","00020","BK1577","09992","BK1116","06058","02889","LU0143863198.USD","03939","BK1170","BK1184","LU0051755006.USD","LU2424517915.HKD","00867","HK0000320264.USD","LU1226288170.HKD","06613","02453","09985","02590","LU0049112450.USD","LU0329678337.USD","BK1523","02627","BK1132"],"gpt_icon":1},{"id":"2588251016","title":"Asian Value Stocks Estimated At 15.2% To 40.3% Below Intrinsic Worth","url":"https://stock-news.laohu8.com/highlight/detail?id=2588251016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588251016?lang=en_us&edition=fundamental","pubTime":"2025-12-03 12:07","pubTimestamp":1764734864,"startTime":"0","endTime":"0","summary":"Amidst a backdrop of global economic uncertainty and shifting monetary policies, Asian markets have shown resilience, with investor interest particularly piqued by the potential for undervalued opportunities. In this context, identifying stocks priced below their intrinsic worth can be a strategic move for investors looking to capitalize on market inefficiencies and long-term growth potential.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/4021000-choice2-main-header/1585186704391","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4021000-choice2-main-header/1585186704391"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/automobiles/shse-600166/beiqi-foton-motorltd-shares/news/asian-value-stocks-estimated-at-152-to-403-below-intrinsic-w","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/automobiles/shse-600166/beiqi-foton-motorltd-shares/news/asian-value-stocks-estimated-at-152-to-403-below-intrinsic-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348827113.USD","LU0561508036.HKD","LU0417516571.SGD","LU2476274308.USD","LU0348766576.USD","09926","LU1961090484.USD","LU0348783233.USD","IE00B543WZ88.USD","LU0417516738.SGD","BK1574","LU0540923850.HKD","LU2399975544.HKD","BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU2476274720.SGD","LU0634319403.HKD","LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516902.SGD","LU0348825331.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2588035860","title":"Asian Growth Stocks With High Insider Ownership December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035860","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588035860?lang=en_us&edition=fundamental","pubTime":"2025-12-02 12:05","pubTimestamp":1764648351,"startTime":"0","endTime":"0","summary":"As Asian markets navigate a complex landscape marked by technological enthusiasm and economic uncertainties, investor interest in growth companies with high insider ownership has intensified. In this environment, stocks characterized by strong insider ownership can offer insights into management confidence and alignment of interests, making them compelling considerations for those looking to understand market dynamics.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/capital-goods/szse-300438/guangzhou-great-power-energy-and-technology-shares/news/asian-growth-stocks-with-high-insider-ownership-december-202","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/capital-goods/szse-300438/guangzhou-great-power-energy-and-technology-shares/news/asian-growth-stocks-with-high-insider-ownership-december-202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU0634319403.HKD","LU2488822045.USD","LU2778985437.USD","LU0417516571.SGD","BK1161","LU1720050803.USD","LU0561508036.HKD","IE00BPRC5H50.USD","BK1574","09926","LU0348766576.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0348827113.USD","LU0540923850.HKD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1961090484.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348825331.USD","LU2399975544.HKD","LU0348735423.USD","LU0348784397.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"1157668357","title":"Southbound Capital Flow Data (T+2) for Dec 2","url":"https://stock-news.laohu8.com/highlight/detail?id=1157668357","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157668357?lang=en_us&edition=fundamental","pubTime":"2025-12-02 07:32","pubTimestamp":1764631967,"startTime":"0","endTime":"0","summary":"On November 27, Alibaba-W (09988), Pop Mart (09992), and China Merchants Bank (03968) topped the market in terms of net southbound capital inflows, recording inflows of HK$911 million, HK$442...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1044875133.USD","LU0738912210.USD","LU1568876335.HKD","LU1831875114.USD","BK1531","LU1951186391.HKD","LU1642822792.SGD","LU0541501648.USD","00777","SG9999014674.SGD","80883","LU0173614495.USD","LU1880383440.USD","BK1512","LU0117841782.USD","SGXZ51526630.SGD","LU0231483743.USD","LU0979878070.USD","HTCD.SI","LU0572940350.SGD","LU1152091754.HKD","BK1607","00107","LU0633140560.USD","BK1183","SG9999015986.USD","LU2488822045.USD","IE00B0169N27.USD","LU1119993845.HKD","LU0672654166.SGD","LU2265009873.SGD","SG9999001226.SGD","IE0008368304.USD","LU0143863198.USD","01186","STAN.UK","03347","BK1224","SG9999002562.SGD","LU2106854487.HKD","LU0210533765.USD","81024","LU1282651048.USD","IE00B5MMRT66.SGD","SG9999012736.USD","02169","LU1048588211.SGD","LU0197773673.USD","SGXZ81514606.USD","LU0499858438.USD","LU2177674079.SGD","01810","BK1523","BK1544","LU2778985437.USD","LU0348814723.USD","LU0107464264.USD","LU1235295612.USD","LU0326950275.SGD","00173","LU1439103000.SGD","LU0702159699.USD","BK1613","03690","LU0370786039.SGD","LU2399975544.HKD","SG9999014898.SGD","BK1501","LU0289960550.SGD","BK1601","LU0543330483.HKD","LU1328277881.USD","LU0868486357.SGD","LU1770036033.HKD","BK1582","01860","LU1733274390.USD","LU1880398554.USD","LU0320764599.SGD","LU2097828474.EUR","IE00BZ08YR35.GBP","BK1541","LU0456842615.SGD","LU0164880469.USD","02255","LU1883866441.USD","SGXZ31699556.SGD","LU2097828805.USD","LU2237443895.HKD","IE0003795394.USD","LU0831093199.SGD","LU0862451837.USD","SG9999001689.USD","LU0449509016.USD","06690","LU0873338254.USD","LU0266512127.USD","LU0608807433.USD","LU0384037296.USD","LU0918141887.USD","02057","LU0831103253.SGD","LU2237443382.USD","LU0211331839.USD","LU0509642566.USD","LU0469268626.HKD","LU0577902454.USD","IE00B8L5B284.USD","LU0456846285.SGD","LU0708995153.HKD","SG9999012744.USD","LU0630378692.HKD","LU0572944931.SGD","LU2097828631.EUR","LU0117844026.USD","LU0348784397.USD","LU0244354667.USD","LU0828237940.HKD","LU1720051017.SGD","IE00B3M56506.USD","03323","BK1555","BK1536","00598","LU2476274720.SGD","LU1282651121.HKD","LU0096374516.USD","LU2125910500.SGD","LU0192582467.USD","LU0143863784.USD","LU0320764243.SGD","LU0577902371.SGD","LU1242518857.USD","BK1618","LU0594300179.USD","BK1592","LU1064130708.USD","LU1282649141.HKD","LU2125910849.SGD","LU0165289439.USD","LU0543330566.HKD","LU0823397285.USD","09988","LU0205439572.USD","LU0737861699.HKD","LU2476274308.USD","LU0130103400.USD","LU0203345920.USD","LU1769817096.USD","IE0008368742.USD","LU1810669033.SGD","LU2097828714.EUR","02628","LU0072913022.USD","00081","LU0345776255.USD","BK1137","LU2008162690.USD","LU2449936058.SGD","IE00BQXX3C00.GBP","BK1241","BK1240","LU0011963245.USD","LU0797268264.HKD","LU1115378108.SGD","LU3063872942.SGD","SG9999000327.SGD","LU0516422952.EUR","LU1242518931.SGD","SG9999003461.SGD","LU1720051108.HKD","LU0329678170.USD","BK1574","LU0708995583.HKD","LU1196710195.USD","BK1141","BK1584","IE00BGHQDM52.EUR","HK0000306701.USD","LU1211504680.USD","LU0516423091.SGD","LU0588545730.USD","LU1814569148.SGD","09880","LU0821914370.USD","LU1497734951.SGD","89988","LU0235996351.USD","BK1198","LU0784639295.USD","LU0871576103.HKD","LU1282649810.SGD","IE00BMCWC346.EUR","BK1609","LU2048586759.USD","LU2357305700.SGD","LU2279701549.SGD","BK1236","LU0737861772.HKD","LU1548497426.USD","LU0823413660.USD","IE00B543WZ88.USD","BK1506","LU0791590937.USD","BK1588","IE00B031HW06.USD","LU1316542783.SGD","LU0634319403.HKD","SG9999007991.SGD","LU0048580855.USD","01361","LU0314109678.HKD","LU1044876610.USD","SG9999015952.SGD","BK1214","SG9999018865.SGD","LU0878004406.USD","LU0865486749.SGD","00981","LU1993786604.SGD","BK1503","LU0348788117.USD","LU2543165471.USD","LU2045819591.USD","LU0463099449.HKD","HK0000500386.USD","IE00B031J352.USD","LU1196710351.USD","LU0293314216.USD","SG9999004220.SGD","LU1328615791.USD","LU0106252389.USD","LU0588546209.SGD","LU0328353924.USD","LU0251144936.SGD","LU1961090484.USD","IE0008369823.USD","IE00B031HY20.USD","LU1634259391.SGD","LU1804176565.USD","BK1572","LU0345769128.USD","LU0577902611.USD","LU0786609619.USD","LU0127658192.USD","LU0039217434.USD","SG9999012728.SGD","02888","IE0008368411.USD","IE00BZ08YT58.USD","LU0210527791.USD","SG9999012710.SGD","LU0210526637.USD","LU0823413587.USD","LU0441854154.USD","LU0132412106.USD","LU0163747925.USD","09606","LU0128522744.USD","LU1366334578.USD","LU0203347892.USD","LU0149721374.USD","LU0211977185.USD","LU0642271901.SGD","IE00BF5LJ272.USD","02899","LU1152091168.USD","LU2251237306.USD","BK1249","LU0823426480.USD","LU2247934214.USD","LU0890818403.SGD","LU0577902538.SGD","LU1323998911.USD","LU0414403682.SGD","BK1591","LU1497733631.SGD","LU1102505929.USD","BK1152","LU2023250504.SGD","LU0531971595.HKD","LU1785774172.SGD","IE00BZ08YS42.EUR","LU0175139822.USD","LU0261950983.USD","LU0502904849.HKD","LU1166156734.SGD","LU2242644610.SGD","LU2362541273.HKD","LU0048597586.USD","LU0359201612.USD","LU2226246903.HKD","LU0359202008.SGD","LU1655091616.SGD","LU1048596156.SGD","BK1526","HXXD.SI","LU0049112450.USD","SG9999001069.SGD","BK1616","SG9999001903.USD","LU0084288322.USD","03877","LU0348767384.USD","LU2097828557.USD","IE0031814852.USD","LU1226288097.SGD","BK1615","BK1095","BK1227","LU1981816686.USD","LU1808992512.USD","LU0264606111.USD","BK1535","GB00BDT5M118.USD","LU1770034418.SGD","SG9999002828.SGD","LU0762542818.HKD","IE0009570106.USD","LU0287142896.SGD","LU0633140727.USD","BK1233","LU0431992006.USD","LU0128522157.USD","LU1515016050.SGD","IE00BPRC5H50.USD","BK1133","LU0348825331.USD","LU1868837565.USD","LU0878005551.USD","HK0000252152.HKD","00700","LU0327786744.USD","BK1563","LU1046422090.SGD","IE00BVYPNQ40.USD","LU0149534421.HKD","LU1226287529.USD","LU0315179316.USD","LU1720050803.USD","IE0003851619.USD","LU0067412154.USD","LU1226287875.USD","LU0648948544.HKD","BK1619","SG9999001846.SGD","IE00B067MR52.USD","LU0348735423.USD","LU1497733557.USD","IE00BGV7N243.SGD","IE0032834883.USD","LU0605514214.HKD","LU0348766576.USD","06818","LU2257852520.SGD","IE00B0JY6N72.USD","LU0348783662.USD","LU0918141705.HKD","LU0828237510.HKD","LU1960683339.HKD","LU0882747503.HKD","SG9999006514.SGD","LU0516423174.USD","LU0307460666.USD","LU0029874905.USD","HK0000165453.HKD","LU0329678337.USD","IE00BVYPNP33.GBP","LU2362541513.USD","LU0531970944.HKD","00762","06969","LU1794554557.SGD","HK0000252160.HKD","BK1505","LU0417516571.SGD","LU0072462343.USD","SG9999000459.SGD","BK1184","BK1507","LU1917777945.USD","IE00BMPRXR70.SGD","SG9999006597.SGD","IE00B97KM107.HKD","LU0588545490.SGD","LU0700851271.USD","LU0169518387.USD","BK1518","LU1188198961.HKD","LU0588545904.SGD","BK1557","LU0593848301.USD","LU0315178854.USD","BK1567","LU1048484197.HKD","IE00BMPRXN33.USD","SG9999002463.SGD","IE0034224299.USD","LU0856984785.SGD","SG9999018857.SGD","LU0540923850.HKD","BK1502","LU0043850808.USD","LU0516422440.USD","LU1226287792.SGD","BK1516","LU0359201885.HKD","LU1044874839.SGD","LU1734074674.USD","LU0577902298.EUR","LU0828238088.HKD","LU1868837722.USD","03968","LU0877626530.USD","BK1142","LU0417516902.SGD","LU0052750758.USD","LU0762541174.USD","BK1104","LU0345775950.USD","LU2293587155.HKD","BK1610","LU2039709279.SGD","BK1575","BK1173","LU0348783233.USD","81810","IE00B0169L03.USD","LU0886674414.USD","LU2251237488.HKD","XIACY","BK1576","SG9999001051.SGD","BK1586","LU0348816934.USD","LU0823426308.USD","LU0985320562.USD","BK1517","LU1725190679.HKD","03033","LU0572939691.SGD","BK1583","LU1105468828.SGD","BK1521","LU0345780281.USD","LU0648000940.SGD","IE00BQXX3F31.USD","LU0823038988.USD","LU0791591158.USD","SG9999014906.USD","LU0501845795.SGD","BK1148","BK1163","LU0214875030.USD","LU2237443549.SGD","00548","LU2148510915.USD","LU1675838814.USD","LU0061477393.USD","BK1614","LU0477156797.USD","LU0823039010.USD","IE0032431581.USD","BK1589","LU1023057109.AUD","SG9999013353.USD","SGXZ62798434.SGD","LU0181495838.USD","HK0000320264.USD","09926","LU1196710864.SGD","BK1151","LU0049853897.USD","LU1251922891.USD","BK1500","LU0054450605.USD","LU0047713382.USD","SG9999017495.SGD","LU0326948709.USD","BK1519","03143","LU1688375341.USD","LU0228659784.USD","LU2133065610.SGD","SG9999015945.SGD","LU0164872284.USD","LU1568876251.USD","LU0499858602.USD","LU1956131251.USD","LU1807302812.USD","IE0003895053.USD","LU0029875118.USD","BK1594","LU0269904917.USD","LU0320764755.SGD","LU1282648689.USD","LU0650527681.SGD","LU1051769294.HKD","IE00B29SXG58.USD","LU0456827905.SGD","LU1201861165.SGD","LU0972618739.USD","LU0229945570.USD","LU2097829019.USD","LU1366334651.USD","LU1481107354.HKD","IE0001KFT4U8.USD","06198","BK1580","LU1439102457.SGD","LU1868838027.USD","LU0417516738.SGD","LU0130518102.USD","KSTmain","BK1135","IE00BYV24P56.USD","LU2317271919.USD","LU1719994722.HKD","LU0675040207.SGD","HK0000306685.HKD","LU0266512473.USD","LU0541502299.USD","LU0051755006.USD","LU0456854461.SGD","00941","LU0164865239.USD","SG9999015978.USD","LU0762540952.USD","SGXZ86797644.SGD","LU1655091459.SGD","BK1242","HBBD.SI","METmain","LU1880398471.USD","LU0188438112.USD","BK1185","LU0880133367.SGD","LU2498475776.HKD","LU0054237671.USD","LU0070217475.USD","LU0396098781.USD","LU0196878994.USD","LU0640798160.USD","LU0819123356.HKD","BK1590","LU0862451753.SGD","HK0000320223.HKD","MPNGY","LU0589944569.HKD","LU0345780521.USD","LU1226288253.USD","LU0630378429.USD","LU0345769631.USD","LU1522347837.USD","IE00B8HQ1Z84.USD","LU0608807946.USD","SGXZ99366536.SGD","LU1102505762.USD","LU1634259557.SGD","LU0254981946.USD","LU0228367735.SGD","LU1974910355.USD","BK1604","LU0702159343.USD","LU0140636845.USD","SGXZ90724238.SGD","LU0048388663.USD","LU0516422366.SGD","LU0106959298.USD","LU0348827113.USD","LU2362540622.SGD","HMTD.SI","BK1550","LU2051468812.USD","LU0611395673.USD","LU1008478684.HKD","LU0348805143.USD","SG9999014880.SGD","LU0080751232.USD","01024","LU0823397103.USD","LU0607220059.USD","LU2237443465.HKD","LU0898667661.SGD","LU0449515922.USD","BK1186","LU0488056044.USD","03441","LU1051768304.USD","SG9999000418.SGD","LU1224709979.USD","LU2152927971.USD","LU0348723411.USD","BK1565","LU1226288170.HKD","LU1880383366.USD","LU1504937902.USD","LU2087589342.USD","LU2237443978.SGD","LU1064131003.USD","LU0197773160.USD","LU0259732245.USD","BK1608","LU0594300419.USD","LU0651947912.USD","LU0561508036.HKD","BK1161","LU1224444064.USD","LU0823040885.USD","LU2462611646.USD","LU1303224171.USD","BK1193","LU0106259558.USD","LU0819121731.USD","LU1813983027.USD","LU2237443622.USD","SG9999001093.SGD","LU1733274473.HKD","LU1718418525.SGD","LU1282649067.USD","BK1231","LU1769817179.HKD","LU0455707207.USD","BK1560","09992","SG9999002950.SGD","02555","LU0261947096.USD","LU0651946864.USD","LU0823041008.USD","LU1629966141.USD","SG9999014914.USD","LU0683595622.HKD","IE00BQXX3D17.EUR"],"gpt_icon":1},{"id":"2586420978","title":"Does Akeso’s (SEHK:9926) First Alzheimer’s Bispecific Antibody Approval Reinvent Its Innovation Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2586420978","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586420978?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:15","pubTimestamp":1764058503,"startTime":"0","endTime":"0","summary":"Earlier this month, Akeso, Inc. announced that its novel bispecific antibody AK152 received approval from the National Medical Products Administration (NMPA) to begin clinical trials for Alzheimer's Disease, marking the first such therapy of its kind developed in China for disease modification. \nThis milestone also signifies Akeso's entry into innovative central nervous system therapeutics, leveraging enhanced brain penetration and robust preclinical results for potential next-generation...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/does-akesos-sehk9926-first-alzheimers-bispecific-antibody-ap","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348825331.USD","LU0634319403.HKD","LU1720050803.USD","LU0348827113.USD","LU2476274308.USD","LU0540923850.HKD","09926","BK1161","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348784397.USD","LU1961090484.USD","LU0417516738.SGD","LU0348783233.USD","LU2399975544.HKD","LU0561508036.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0348735423.USD","LU0348766576.USD","LU2778985437.USD","LU0348767384.USD","LU1794554557.SGD","LU2476274720.SGD","LU2488822045.USD","BK1574"],"gpt_icon":0},{"id":"2585197407","title":"Akeso (SEHK:9926) Valuation: Assessing Pipeline Momentum After Landmark Alzheimer’s and Oncology R&D Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2585197407","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585197407?lang=en_us&edition=fundamental","pubTime":"2025-11-21 11:26","pubTimestamp":1763695588,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has just been cleared by China’s National Medical Products Administration to initiate clinical trials for AK152, its first bispecific antibody aimed at tackling Alzheimer’s Disease, and a breakthrough in the domestic biotech space.\nSee our latest analysis for Akeso.\nWhile Akeso's progress on Alzheimer's and its oncology advances have kept it in the headlines, the share price has pulled back 36% over the past three months after a rapid rally earlier this year. Still, the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-assessing-pipeline-momentum-after-l","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-assessing-pipeline-momentum-after-l","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417516571.SGD","IE00B19Z3B42.SGD","LU0348767384.USD","IE00BBT3K403.USD","LU1720050803.USD","IE000M9KFDE8.USD","LU0348827113.USD","LU0289739699.SGD","LU0868494617.USD","BK1161","LU0540923850.HKD","LARK","LU0561508036.HKD","BK4550","BK4534","LU0348783233.USD","LU0321505439.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU2488822045.USD","SG9999002224.SGD","LU1883839398.USD","IE00B19Z3581.USD","BK1574","LU1894683348.USD","LU1066051498.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU2399975544.HKD","SG9999001176.SGD","BK4211","LU0634319403.HKD","BK4585","IE00B5MMRT66.SGD","LU0306807586.USD","SG9999011175.SGD","SGXZ57979304.SGD","BK4533","SG9999013999.USD","BK4588","09926","LU2778985437.USD","LU0321505868.SGD","LU0348766576.USD","LU1961090484.USD","IE0002270589.USD","LU0348825331.USD","LU1023059063.AUD","LU1057294990.SGD"],"gpt_icon":1},{"id":"2584349618","title":"Akeso Wins China Approval to Begin Clinical Trials of Bispecific Antibody for Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2584349618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584349618?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:29","pubTimestamp":1763346595,"startTime":"0","endTime":"0","summary":"Akeso Inc. has received regulatory approval from China's National Medical Products Administration  to initiate clinical trials for AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and a blood-brain barrier  expressed receptor for the treatment of Alzheimer's Disease. AK152 is the first bispecific antibody developed in China for this indication, marking a significant advancement in disease-modifying therapy for Alzheimer's. The approval allows Akeso to begin clinical studies, following promising preclinical results demonstrating robust bioactivity, improved brain penetration, and accelerated clearance of Aβ plaques. No other organizations were mentioned as recipients of this approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLbhZXxt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0561508036.HKD","LU0417516571.SGD","LU2476274308.USD","LU0348766576.USD","09926","LU1961090484.USD","LU0348783233.USD","IE00B543WZ88.USD","LU0417516738.SGD","BK1574","LU0540923850.HKD","LU2399975544.HKD","BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU2476274720.SGD","LU0634319403.HKD","LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516902.SGD","LU0348825331.USD","LU1720050803.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":0.0578},{"period":"3month","weight":-0.0812},{"period":"6month","weight":0.2989},{"period":"1year","weight":0.8892},{"period":"ytd","weight":1.0511}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.000596},{"month":2,"riseRate":0.4,"avgChangeRate":0.029178},{"month":3,"riseRate":0.4,"avgChangeRate":-0.035342},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.5,"avgChangeRate":0.043874}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}